Report
Autolus Launch continues, FY25 beat is within reach
Autolus reported 3Q25 sales of $ 21.1m which came in slightly below CSS expectations of $ 21.9m. However, deferred revenue of $ 7.6m was significantly higher than the previous quarter giving us confidence that FY25 expectations are achievable. Additionally, at ASH 2025 Autolus plans to present longer follow-up in SLE and initial data in pediatric ALL, the topline results indicate a competitive profile against Kymriah. Autolus reiterated its plans to start a pivotal study in LN and a phase 1 in AL amyloidosis by YE25. These added indications should provide Autolus with additional growth drivers for the future. We reiterate our BUY and $ 10 TP.
Underlying
Autolus Therapeutics ADS
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Mathijs Geerts Danau
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.